Eisai Co (4523N) Q1 2026 Earnings Report

The call conveys clear commercial momentum and strong financial improvement driven by the flagship products (notably LEQEMBI and LENVIMA), meaningful cost-efficiency gains, and reinforcing clinical and real-world evidence. Key near-term catalysts include SC‑AI approval, BBM reimbursement and ongoing DTC/pathway initiatives. Material risks discussed include pricing and HTA uncertainty in Japan, potential tariff/MFN policy impacts, reimbursement execution (Medicare Part B to D transition) and competitive entrants. On balance the positives — robust revenue and profit growth, expanding diagnostics and pathway adoption, favorable clinical data and operating leverage — outweigh the uncertainties, though continued monitoring of pricing/reimbursement and geopolitical policy is warranted.

Management reiterated there is no change to the consolidated FY2025 forecast and said Q1 was a strong start: consolidated revenue JPY202.7bn (+7% YoY; FX headwind JPY10.1bn), pharmaceutical revenue JPY198.4bn (+6%), gross profit JPY160.1bn (+7%) with cost of sales JPY42.6bn (cost ratio 21%), R&D JPY38.8bn (93% of prior year; 19.1% of revenue, down ~3ppt from 22.1%), SG&A JPY100.2bn (+1%, including JPY36.0bn shared profit), operating profit JPY20.7bn (+55%), net profit JPY15.3bn (+33%) and profit attributable to owners JPY14.5bn (+37%); 3Ls (LENVIMA, LEQEMBI, DAYVIGO) totaled JPY120.7bn (+19% YoY) with LEQEMBI driving a JPY16.9bn uplift. Product guidance reiterated: LEQEMBI Q1 sales JPY23.1bn and FY2025 sales target JPY76.5bn, LENVIMA Q1 JPY83.9bn and FY2025 target JPY312bn; company targets FY2026 ROE 8% and revenue JPY790bn/operating profit JPY54.5bn. Key operational catalysts and timing noted include the SC‑AI PDUFA action date Aug 31 (360 mg weekly SC‑AI shown equivalent to 10 mg/kg monthly IV), BBM diagnostic guidance (triage tests ≥90% sensitivity/≥75% specificity; substitute tests ≥90%/≥90%) and expected BBM reimbursement/pricing from January, plus demand indicators such as US LEQEMBI +20% QoQ (CER), BBM tests +130% average growth, PET/CSF tests +120% average growth, Japan wholesaler shipments 130% QoQ and 1,500 follow‑up facilities established.